Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POZ in Treatment-Naive Mantle Cell Lymphoma
NCT07257510Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- IgG Antibodies, Molecular Glues
- Countries
- 1
01
Overview
Open-label, single-arm trial of pomalidomide, orelabrutinib and hlx01 in mantle cell lymphoma (MCL), sponsored by Peking University Third Hospital. Primary endpoint: Minimum Residual Disease Rate at 6 months. Started Aug 2025; status: recruiting.
02
Drugs
pomalidomideorelabrutinibhlx01
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07257510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07257510.